US-based digital health company Profusa, Inc. (NASDAQ: PFSA), which develops tissue-integrated biosensors for continuous biochemical monitoring, announced on Friday the launch of a healthcare research version of its Lumee tissue oxygen monitoring system for the contract research organisations market.

The company said the move is expected to generate immediate service-based revenue.

The research-use-only Lumee tissue oxygen system is commercially ready and available for immediate deployment, enabling CRO partners to integrate continuous, real-time tissue oxygen measurement into existing study designs with minimal implementation risk. The platform is designed to support applications including advanced in vitro and organ-on-chip models, preclinical pharmacology and toxicology, translational research, wound healing and oncology research.

Profusa is targeting the global pharmaceutical CRO market, estimated at about USD47.9bn in 2025 and forecast to grow at more than 7% compound annual growth to over USD91.2bn by 2034. The company said that market growth is being driven by rising R&D investment, regulatory momentum around new approach methodologies and efforts to reduce late-stage development risk.